FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891621703> ?p ?o ?g. }

• W2891621703 endingPage "1337" @default.
• W2891621703 startingPage "1328" @default.
• W2891621703 abstract "BackgroundAdverse effects on reproductive function are a key concern in young women treated with chemotherapy for advanced Hodgkin's lymphoma. We aimed to identify risk factors for the extent of ovarian damage in women with Hodgkin's lymphoma treated with different chemotherapy regimens to inform accurate advice on options for fertility preservation.MethodsWe recruited female participants from the randomised phase 3 RATHL trial, aged 18–45 years, based on availability of participants at recruiting sites in the UK. The RATHL trial key inclusion criteria were histologically confirmed classic Hodgkin's lymphoma, stage IIB–IV or IIA with adverse features (bulky disease or more than two sites of involvement), no previous treatments, and a performance status of 0–3. As part of RATHL, participants were treated with two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or AVD followed by an interim PET-CT scan. Participants who had negative interim scans (PET score of 1 to 3 according to the Lugano classification) were randomly assigned (1:1) by use of minimisation, stratified by interim PET score and study centre, to continue ABVD or AVD for four more cycles. Participants with positive scans (PET score of 4 or 5) were escalated to treatment with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisolone (BEACOPP-14 or escalated BEACOPP) for four cycles. For the protocol-driven prospective cohort substudy, ovarian function was assessed before treatment, during chemotherapy, and then annually for 3 years by use of serum antimüllerian hormone and follicle-stimulating hormone measurements. The RATHL study is registered with ClinicalTrials.gov, number NCT00678327.FindingsBetween Dec 13, 2010, and Dec 19, 2012, 67 eligible participants were recruited for this prospective cohort study; 57 had received ABVD or AVD (ABVD-AVD group) and ten BEACOPP-14 or escalated BEACOPP (BEACOPP group). Follow-up was fixed at 3 years. Antimüllerian hormone concentrations decreased during both chemotherapy regimens. At 1 year after chemotherapy, antimüllerian hormone concentrations recovered to a median of 10·5 pmol/L (IQR 4·3–17·3) in the ABVD-AVD group, but little recovery was seen after BEACOPP (median 0·11 pmol/L [0·07–0·20]). Age also affected the extent of ovarian function recovery, with antimüllerian hormone recovery in participants aged 35 years or older in the ABVD-AVD group to 37% (SD 10) of their before treatment concentrations, compared with full recovery to 127% (SD 12) in those younger than 35 years (p<0·0001). Follicle-stimulating hormone recovery to less than 25 IU/L occurred for 95% of women younger than 35 years in the ABVD-AVD group by 2 years and was also dependent on age (hazard ratio 0·49, 95% CI 0·37–0·65; p<0·0001).InterpretationReduced recovery of ovarian function observed in women older than 35 years treated with ABVD or AVD compared with younger women indicates that treatment could reduce their reproductive lifespan and supports discussion of fertility preservation before treatment. Women treated with BEACOPP should be informed of its potential high gonadotoxicity. These findings warrant further investigation in large, prospective studies with fertility and reproductive lifespan as outcomes.FundingMedical Research Foundation and Cancer Research UK." @default.
• W2891621703 created "2018-09-27" @default.
• W2891621703 creator A5007119947 @default.
• W2891621703 creator A5014125875 @default.
• W2891621703 creator A5016957205 @default.
• W2891621703 creator A5018708168 @default.
• W2891621703 creator A5020021596 @default.
• W2891621703 creator A5023490544 @default.
• W2891621703 creator A5028516152 @default.
• W2891621703 creator A5039023166 @default.
• W2891621703 creator A5050819642 @default.
• W2891621703 creator A5068239780 @default.
• W2891621703 creator A5073849951 @default.
• W2891621703 creator A5085369076 @default.
• W2891621703 creator A5086703193 @default.
• W2891621703 creator A5090701139 @default.
• W2891621703 date "2018-10-01" @default.
• W2891621703 modified "2023-10-15" @default.
• W2891621703 title "Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial" @default.
• W2891621703 cites W1505571525 @default.
• W2891621703 cites W1958707516 @default.
• W2891621703 cites W1976281058 @default.
• W2891621703 cites W1984310422 @default.
• W2891621703 cites W2003583785 @default.
• W2891621703 cites W2008127541 @default.
• W2891621703 cites W2051162959 @default.
• W2891621703 cites W2053064720 @default.
• W2891621703 cites W2061215876 @default.
• W2891621703 cites W2101407679 @default.
• W2891621703 cites W2132696402 @default.
• W2891621703 cites W2135143061 @default.
• W2891621703 cites W2136159364 @default.
• W2891621703 cites W2136336924 @default.
• W2891621703 cites W2139777504 @default.
• W2891621703 cites W2226497166 @default.
• W2891621703 cites W2290318229 @default.
• W2891621703 cites W2309700868 @default.
• W2891621703 cites W2401733179 @default.
• W2891621703 cites W2405943166 @default.
• W2891621703 cites W2469052042 @default.
• W2891621703 cites W2497766038 @default.
• W2891621703 cites W2608327819 @default.
• W2891621703 cites W2610608850 @default.
• W2891621703 cites W2753268315 @default.
• W2891621703 cites W2761047277 @default.
• W2891621703 cites W2766021007 @default.
• W2891621703 cites W2790489327 @default.
• W2891621703 cites W2802421801 @default.
• W2891621703 doi "https://doi.org/10.1016/s1470-2045(18)30500-x" @default.
• W2891621703 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6167406" @default.
• W2891621703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30220622" @default.
• W2891621703 hasPublicationYear "2018" @default.
• W2891621703 type Work @default.
• W2891621703 sameAs 2891621703 @default.
• W2891621703 citedByCount "56" @default.
• W2891621703 countsByYear W28916217032018 @default.
• W2891621703 countsByYear W28916217032019 @default.
• W2891621703 countsByYear W28916217032020 @default.
• W2891621703 countsByYear W28916217032021 @default.
• W2891621703 countsByYear W28916217032022 @default.
• W2891621703 countsByYear W28916217032023 @default.
• W2891621703 crossrefType "journal-article" @default.
• W2891621703 hasAuthorship W2891621703A5007119947 @default.
• W2891621703 hasAuthorship W2891621703A5014125875 @default.
• W2891621703 hasAuthorship W2891621703A5016957205 @default.
• W2891621703 hasAuthorship W2891621703A5018708168 @default.
• W2891621703 hasAuthorship W2891621703A5020021596 @default.
• W2891621703 hasAuthorship W2891621703A5023490544 @default.
• W2891621703 hasAuthorship W2891621703A5028516152 @default.
• W2891621703 hasAuthorship W2891621703A5039023166 @default.
• W2891621703 hasAuthorship W2891621703A5050819642 @default.
• W2891621703 hasAuthorship W2891621703A5068239780 @default.
• W2891621703 hasAuthorship W2891621703A5073849951 @default.
• W2891621703 hasAuthorship W2891621703A5085369076 @default.
• W2891621703 hasAuthorship W2891621703A5086703193 @default.
• W2891621703 hasAuthorship W2891621703A5090701139 @default.
• W2891621703 hasBestOaLocation W28916217031 @default.
• W2891621703 hasConcept C126322002 @default.
• W2891621703 hasConcept C141071460 @default.
• W2891621703 hasConcept C143998085 @default.
• W2891621703 hasConcept C2776305933 @default.
• W2891621703 hasConcept C2776694085 @default.
• W2891621703 hasConcept C2776755627 @default.
• W2891621703 hasConcept C2777132456 @default.
• W2891621703 hasConcept C2778336483 @default.
• W2891621703 hasConcept C2779112685 @default.
• W2891621703 hasConcept C2779429289 @default.
• W2891621703 hasConcept C2780964509 @default.
• W2891621703 hasConcept C71924100 @default.
• W2891621703 hasConceptScore W2891621703C126322002 @default.
• W2891621703 hasConceptScore W2891621703C141071460 @default.
• W2891621703 hasConceptScore W2891621703C143998085 @default.
• W2891621703 hasConceptScore W2891621703C2776305933 @default.
• W2891621703 hasConceptScore W2891621703C2776694085 @default.
• W2891621703 hasConceptScore W2891621703C2776755627 @default.
• W2891621703 hasConceptScore W2891621703C2777132456 @default.
• W2891621703 hasConceptScore W2891621703C2778336483 @default.
• W2891621703 hasConceptScore W2891621703C2779112685 @default.

• next